Chloroethylclonidine and alpha-adrenoceptor agonist interaction in blood vessels following heart failure.

[1]  C. Forster.  Interaction of 5-methyl-urapidil with alpha 1-adrenoceptors in canine blood vessels: impact of pacing-induced heart failure. , 1996, European journal of pharmacology.

[2]  E. Daniel,et al.  Unusual αadrenoceptor subtype in canine saphenous vein: comparison to mesenteric vein , 1996 .

[3]  C. Forster,et al.  Coronary β-adrenoceptor function is modified by the endothelium in heart failure , 1996 .

[4]  J. Docherty,et al.  Investigation of the actions of chloroethylclonidine in rat aorta , 1995, British journal of pharmacology.

[5]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[6]  A. M. Low,et al.  Interactions of chloroethylclonidine with rauwolscine‐ and prazosin‐sensitive adrenoceptors in dog saphenous vein , 1994, British journal of pharmacology.

[7]  A. Ford,et al.  α1-Adrenoceptor classification: sharpening Occam's razor , 1994 .

[8]  D. Girdlestone,et al.  TiPS receptor and ion channel nomenclature supplement 1994 , 1994 .

[9]  T. Branchek,et al.  Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. , 1993, Molecular pharmacology.

[10]  J. Mironneau,et al.  Relation between α1‐adrenoceptor subtypes and noradrenaline‐induced contraction in rat portal vein smooth muscle , 1993, British journal of pharmacology.

[11]  H. Hartman,et al.  Cardiovascular effects of chloroethylclonidine, an irreversible alpha 1B-adrenoceptor antagonist, in the unanesthetized rat: a pharmacological analysis in vivo and in vitro. , 1993, The Journal of pharmacology and experimental therapeutics.

[12]  J. Docherty,et al.  Investigation of the subtypes of α1‐adrenoceptor mediating contractions of rat aorta, vas deferens and spleen , 1993, British journal of pharmacology.

[13]  P. Armstrong,et al.  Temporal Alterations in Peripheral Vascular Responsiveness During Both the Development and Recovery from Pacing‐Induced Heart Failure , 1992, Journal of cardiovascular pharmacology.

[14]  W. Parmley,et al.  Pathophysiology of congestive heart failure. , 1985, Clinical cardiology.

[15]  M. Oriowo,et al.  Activation of a single alpha-1-adrenoceptor subtype in rat aorta mobilizes intracellular and extracellular pools of calcium. , 1992, Pharmacology.

[16]  R. Graham,et al.  Solution-phase library screening for the identification of rare clones: isolation of an alpha 1D-adrenergic receptor cDNA. , 1991, Molecular pharmacology.

[17]  M. Caron,et al.  Molecular biology of α-adrenergic receptors: implications for receptor classification and for structure-function relationships , 1991 .

[18]  P. Armstrong,et al.  Novel vascular effects of isoprenaline following pacing-induced heart failure in the dog. , 1991, European journal of pharmacology.

[19]  M. Piascik,et al.  Evidence for a complex interaction between the subtypes of the alpha 1-adrenoceptor. , 1991, European journal of pharmacology.

[20]  M. Barras,et al.  α‐Adrenoceptor subtypes in dog saphenous vein that mediate contraction and inositol phosphate production , 1991, British journal of pharmacology.

[21]  P. Armstrong,et al.  Pacing-Induced Heart Failure in the Dog: Evaluation of Peripheral Vascular α-Adrenoceptor Subtypes , 1990, Journal of cardiovascular pharmacology.

[22]  M. Caron,et al.  Molecular cloning and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype. , 1990, The Journal of biological chemistry.

[23]  J. Bevan,et al.  Chloroethylclonidine unmasks a non-α-adrenoceptor noradrenaline binding site in the rat aorta , 1990 .

[24]  P. Armstrong,et al.  Vascular smooth muscle responsiveness to noradrenaline and phenylephrine following experimental heart failure in dogs. , 1989, Cardiovascular research.

[25]  P. Armstrong,et al.  α1-Adrenoceptor activity in arterial smooth muscle following congestive heart failure , 1989 .

[26]  J. Docherty.  The pharmacology of α1- and α2-adrenoceptors: Evidence for and against a further subdivision , 1989 .

[27]  M. Caron,et al.  Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Gross,et al.  5-Methyl-urapidil discriminates between subtypes of the α1-adrenoceptor , 1988 .

[29]  P. Abel,et al.  Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine. , 1987, Molecular pharmacology.

[30]  P. Abel,et al.  α1Adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle , 1987, Nature.

[31]  P. Armstrong,et al.  Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. , 1986, Circulation.

[32]  R. Coleman,et al.  Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. , 1986, The American journal of cardiology.

[33]  I. Creese,et al.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. , 1986, Molecular pharmacology.

[34]  J. T. Herlihy,et al.  Effect of preload on rat aortic smooth muscle sensitivity to vasoactive agents. , 1986, Pharmacology.

[35]  C. Dollery,et al.  Drug treatment of heart failure. , 1985, British heart journal.

[36]  R. B. Parker,et al.  Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists. , 1971, The Journal of pharmacology and experimental therapeutics.